0002051051-25-000001.txt : 20250107 0002051051-25-000001.hdr.sgml : 20250107 20250106175102 ACCESSION NUMBER: 0002051051-25-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20250107 DATE AS OF CHANGE: 20250106 EFFECTIVENESS DATE: 20250107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rila Therapeutics, Inc. CENTRAL INDEX KEY: 0002051051 ORGANIZATION NAME: IRS NUMBER: 861457464 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-534373 FILM NUMBER: 25512628 BUSINESS ADDRESS: STREET 1: 280 UTAH AVENUE STREET 2: SUITE 250 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-410-5000 MAIL ADDRESS: STREET 1: 280 UTAH AVENUE STREET 2: SUITE 250 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 D 1 primary_doc.xml X0708 D LIVE 0002051051 Rila Therapeutics, Inc. 280 UTAH AVENUE SUITE 250 SOUTH SAN FRANCISCO CA CALIFORNIA 94080 650-410-5000 DELAWARE None None Corporation true 2021 Robert Drakas c/o Rila Therapeutics, Inc. 280 Utah Avenue, Suite 250 South San Francisco CA CALIFORNIA 94080 Executive Officer Director William Dai c/o Rila Therapeutics, Inc. 280 Utah Avenue, Suite 250 South San Francisco CA CALIFORNIA 94080 Director Michael Hui c/o Rila Therapeutics, Inc. 280 Utah Avenue, Suite 250 South San Francisco CA CALIFORNIA 94080 Director Biotechnology Decline to Disclose 06b false 2024-12-20 false true false 0 10759378 6978195 3781183 The offering includes equity issued for consideration other than cash and as such the amounts entered are based on the issuer's good faith valuation of the consideration. false 3 0 0 0 true The proceeds are available to fund general working capital requirements; as of the date of this filing no detailed operating budget has been adopted; and no proceeds have been or are proposed to be used for payments of compensation. false Rila Therapeutics, Inc. /s/ Robert Drakas Robert Drakas President 2025-01-06